Lexaria Bioscience Corp. Warrant
LEXXW
About: Lexaria Bioscience Corp's patented drug delivery technology, DehydraTECH improves the way active pharmaceutical ingredients enter the bloodstream by promoting more effective oral delivery. DehydraTECH can increase bio-absorption with cannabinoids and nicotine by 5-10x and, in some instances with cannabinoids by as much as 27x compared to standard industry formulations, reduce the time of onset from 1-2 hours to minutes, and mask unwanted tastes. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood-brain barrier. The company has four reportable segments: Intellectual Property Licensing which generates maximum revenue, B2B Production, Research and Development, and Corporate. Geographically, it derives revenue from the United States and Canada.
Employees: 7
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
4.26% more ownership
Funds ownership: 0% [Q1] → 4.26% (+4.26%) [Q2]
0% more funds holding
Funds holding: 2 [Q1] → 2 (+0) [Q2]
70% less capital invested
Capital invested by funds: $15K [Q1] → $4.55K (-$10.4K) [Q2]
Financial journalist opinion
We haven’t received any recent news articles for LEXXW